ultimate i & ii results: ublituximab versus teriflunomide in relapsing ms
Published 3 years ago • 494 plays • Length 3:27Download video MP4
Download video MP3
Similar videos
-
3:26
phase iii ultimate i & ii update: ublituximab versus teriflunomide in relapsing ms
-
1:52
relapse rate from the ultimate studies of ublituximab for relapsing ms
-
1:41
ublituximab: pending approval for relapsing ms
-
1:14
how does ublituximab compare to other anti-cd20 mabs?
-
5:42
comparing ublituximab and teriflunomide in improving fatigue in ms
-
2:13
is long-term teriflunomide treatment safe in ms?
-
2:12
terikids study: teriflunomide in pediatric patients with relapsing ms
-
1:08
post-authorization safety study of teriflunomide in ms
-
2:28
tolebrutinib reduces new mri lesions in highly active relapsing ms
-
4:51
teriflunomide shows benefits in longterm care of multiple sclerosis
-
59:51
introducing the ultimate ms treatment guide: expanding your ms shared-management tool repository
-
3:08
novel agents are needed for the treatment of multiple sclerosis
-
3:02
omicron sub-variants spread in u.s. as metro detroit doctors urge bivalent booster
-
2:50
long-term treatment with anti-cd20 mabs - is it feasible?
-
4:00
umbralisib ublituximab shows superior outcomes to standard of care chemoimmunotherapy in cll
-
4:38
briumvi for multiple sclerosis | effectiveness | side effects
-
4:18
determining the optimal treatment strategy in ms
-
3:11
opic extension study: teriflunomide a "well tolerated" oral agent for long-term multiple sclerosis
-
1:16
latest advances in immunotherapy for multiple myeloma: targets, allocar-ts & immunomodulatory drugs